
UNICEF Announces New Deal for Low-cost Five-in-one Vaccine for Children
The United Nations Children’s Fund (UNICEF) has partnered with six vaccine makers and the Global Alliance for Vaccines and Immunization (GAVI) to offer 450 million doses of an inexpensive pentavalent vaccine for children.
A recent announcement from the United Nations Children’s Fund (UNICEF) outlines a new effort promising a sustainable and low-cost five-in-one vaccine for children at the highest risk for catching deadly diseases through a partnership with vaccine suppliers.
According to the World Health Organization’s (WHO)
A recent
Under the new initiative, UNICEF has partnered with six vaccine suppliers to buy 450 million doses of the pentavalent vaccine at only 84 cents per piece, nearly cutting half the current cost that the agency pays for each dose. In collaboration with vaccine companies Biology E, Jenssen, LG Life Sciences, Panacea Biotec Ltd, Serum Institute of India, and Shantha Biotechs, UNICEF aims to bring down the toll of deadly infections ranging from diphtheria, tetanus, pertussis, hepatitis B, to Haemophilus influenzae type B.
According to UNICEF, from 2001 to 2015, the agency was able to increase the number of pentavalent doses they bought from 14.5 million to 235 million. With the new effort nearly doubling the number of available doses, the vaccines will be distributed to 80 countries over the next 3 years. Countries supported by the
In addition to the countries receiving these vaccines from UNICEF, other governments able to purchase the five-in-one vaccine will also have access to the new reduced pricing. For the health officials, donors, organizations, and suppliers involved in this new initiative, the goal is to avoid shortages and create an excess supply of vaccines by working with multiple vaccine developers that have signed multi-year contracts.
“Gavi estimates that 5.7 million deaths will be averted thanks to pentavalent vaccination in Gavi-supported countries between 2011 and 2020,” said Seth Berkley, MD, CEO of Gavi, in a the press release. “The market for five-in-one vaccines is now a lot healthier than it was just a few years ago thanks to our collective efforts to grow a base of vaccine suppliers. We remain committed to making vaccine markets work better for the world’s poorest countries to ensure immunization investments and efforts are sustainable for all."
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.